Development, In-Vitro Evaluation And In-Vivo Pharmacokinetic Study Of Buspirone Hcl Solid Lipid Nanoparticles

Abstract

Buspirone hydrochloride (BUS HCl) treats anxiety disorders and relieves symptoms, however its bioavailability is 4–10%. Solid lipid nanoparticles (SLNs) are commonly spherical with a 50 to 1000 nm diameter. The objective of the study to develop solid lipid nanoparticles and improve the oral bioavailability of buspirone HCl. Differential scanning calorimetry (DSC) studies showed no interactions between drugs and lipids. The SLNs were designed through a process of hot homogenization followed by ultrasonication. The prepared formulations were evaluated for size, zeta potential (ZP), Polydispersity Index (PDI), entrapment efficiency (EE), in-vitro drug release, and stability studies. Field emission scanning electron microscopy (FESEM) studies revealed that pure drug had irregular particles, whereas SLNs contained spherical-shaped and uniform-sized particles. Based upon the results, F3 formulation was optimized having size (163.1±5.2nm), PDI (0.163±0.007), and showed in-vitro release (76.44±1.4%) in 24hrs. The formulation (F3) significantly improved pharmacokinetic parameters such as Cmax, AUC0-t, and t1/2 and increased bioavailability by 2.3 folds that of coarse suspension.